Horizon Pharma PLC (HZNP) was Upgraded by Citigroup to ” Buy”. Earlier the firm had a rating of “Neutral ” on the company shares. Citigroup advised their investors in a research report released on Nov 28, 2016.
Many Wall Street Analysts have commented on Horizon Pharma PLC. Company shares were Reiterated by Mizuho on Nov 8, 2016 to “Buy”, Firm has raised the Price Target to $ 30 from a previous price target of $29 .Shares were Reiterated by Mizuho on Oct 31, 2016 to “Buy” and Lowered the Price Target to $ 29 from a previous price target of $33 .Company shares were Reiterated by Mizuho on Sep 13, 2016 to “Buy”, Firm has raised the Price Target to $ 33 from a previous price target of $30 .
On the company’s financial health, Horizon Pharma PLC reported $0.70 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Nov 7, 2016. Analyst had a consensus of $0.62. The company had revenue of $273.70 million for the quarter, compared to analysts expectations of $272.03 million. The company’s revenue was up 20.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 EPS.
Horizon Pharma PLC closed down -0.21 points or -0.97% at $21.49 with 6,30,634 shares getting traded on Friday. Post opening the session at $21.75, the shares hit an intraday low of $21.32 and an intraday high of $21.75 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Aug 2, 2016, Jeffrey W Sherman (EVP and Chief Medical Officer) sold 2,900 shares at $20.00 per share price. According to the SEC, on Jun 15, 2016, Virinder Nohria (director) sold 25,000 shares at $17.69 per share price. On Aug 21, 2015, Thomas Watkins (director) purchased 10,000 shares at $31.32 per share price, according to the Form-4 filing with the securities and exchange commission.
Horizon Pharma plc formerly Vidara Therapeutics International Public Limited Company is a specialty biopharmaceutical company focused on identifying developing acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis inflammation and orphan diseases. The Company’s the United States marketed products are ACTIMMUNE (interferon gamma-1b) DUEXIS (ibuprofen/famotidine) PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA has the United States rights to VIMOVO has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.